Related Experiment Video
Updated: Jun 4, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Hypoxia potentiates glioma-mediated immunosuppression
Jun Wei1, Adam Wu, Ling-Yuan Kong
1Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Plos One
|February 2, 2011
Summary
Tumor hypoxia in glioblastoma (GBM) significantly worsens immune suppression by cancer stem cells. Inhibiting STAT3 and HIF-1α pathways reversed these immunosuppressive effects, offering new therapeutic strategies for GBM.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Glioblastoma multiforme (GBM) is a fatal brain tumor characterized by profound immune suppression.
- Tumor hypoxia is a common feature of GBM, but its precise role in immune evasion is not fully understood.
- GBM-associated cancer stem cells (gCSCs) are resistant to treatment and known to suppress immune responses.
Purpose of the Study:
- To investigate the impact of hypoxia on the immunosuppressive properties of gCSCs.
- To elucidate the molecular mechanisms underlying hypoxia-driven immunosuppression in GBM.
- To evaluate the therapeutic potential of targeting hypoxia-related pathways in GBM immunotherapy.
Main Methods:
- Comparison of gCSC immunosuppressive functions under normoxic and hypoxic conditions.
- Assessment of cytokine/chemokine production, T cell proliferation and activation, regulatory T cell induction, and macrophage phenotype.
- Analysis of the role of signal transducer and activator of transcription 3 (STAT3), hypoxia-inducible factor-1α (HIF-1α), and vascular endothelial growth factor (VEGF).
- Evaluation of STAT3 and HIF-1α inhibitors on gCSC-mediated immunosuppression.
Main Results:
- Hypoxia significantly enhanced gCSC-mediated inhibition of T cell proliferation and activation.
- Hypoxia potentiated the induction of FoxP3+ regulatory T cells and further suppressed macrophage phagocytosis.
- Hypoxia-induced immunosuppression was dependent on STAT3 signaling, leading to increased HIF-1α and VEGF expression.
- Inhibition of STAT3 and HIF-1α reversed the hypoxia-enhanced immunosuppressive effects of gCSCs.
Conclusions:
- Tumor hypoxia exacerbates GBM's immune suppressive microenvironment by enhancing gCSC-mediated immune evasion.
- Targeting STAT3 and HIF-1α pathways represents a promising strategy to overcome hypoxia-driven immunosuppression in GBM.
- Understanding the role of tumor hypoxia is crucial for developing effective immunotherapies for GBM patients.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...